Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE

Completed · Phase 3

Conditions studied: Neuroendocrine Tumors

In brief

This is an open-label, single-dose, single-arm, single-center imaging study using DOTATATE peptide, labelled with the 64Cu tracer.

Key facts

Study ID

NCT03673943

Run by

Radiomedix, Inc.

People needed

63

Starts

2018-08-23

Expected to finish

2019-08-07

Last updated by the study team

2022-12-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Confirmed or suspicion of NET based on histology/ biopsy report.
• Confirmed or suspicion of NET based on conventional imaging scans of affected area such as MRI and/or contrast enhanced CT and/or an FDG PET
• CT scan and/or NaF PET-CT scan and/or OctreoScan® performed within 8 weeks prior to study date.

You may not qualify if…

• Pregnant, planning to be pregnant within the next two weeks
• Inability to provide written consent.
• Therapeutic use of any somatostatin analogue, including Sandostatin® long-acting and Lanreotide (within 28 days) and Sandostatin® (within 2 days) prior to study imaging. If a subject is on Sandostatin® long-acting or Lanreotide, a wash-out period of 28 days is required before the injection of the study drug.

Where it is running

• Excel Diagnostics and Nuclear Oncology Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.